Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9269074 | 0.94 | MAOB (0.53) | TAAR1AOC3MAOBIDO1ALDH1A1 | |
| SCHEMBL1338713 | 0.87 | NR3C1 (0.44) | TAAR1AOC3MAOB | |
| SCHEMBL3655884 | 0.86 | KCNH2 (0.47) | TAAR1AOC3MAOBALDH1A1KDM4E | |
| SCHEMBL11959867 | 0.85 | IGF1R (0.48) | TAAR1AOC3KDM4EHTR3EHTR3B | |
| SCHEMBL11959919 | 0.83 | KCNH2 (0.49) | TAAR1AOC3KDM4EHTR3EHTR3B | |
| SCHEMBL9270819 | 0.81 | MAOB (0.50) | TAAR1AOC3MAOBKDM4ESLC6A2 | |
| SCHEMBL2412500 | 0.81 | ADRB2 (0.42) | TAAR1MAOBKDM4E | |
| SCHEMBL11228865 | 0.80 | TAAR1 (0.54) | TAAR1AOC3MAOBIDO1AGXT | |
| SCHEMBL12926311 | 0.80 | MAOB (0.48) | TAAR1MAOBALDH1A1KDM4E | |
| SCHEMBL9270269 | 0.78 | MAOB (0.47) | TAAR1MAOBALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177601-B1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | SCRIPPS RESEARCH INST (US) | 2023-03-01 | — | — | EP | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8722942-B2 | Method for producing biphenyl derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2075241-B1 | METHOD FOR PRODUCING A BIPHENYL DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2013-09-25 | — | — | EP | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | Hayashi, Tamio (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2075241-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | TAAR1 2082/4885AOC3 149/4885MAOB 274/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | TAAR1 2082/4885AOC3 149/4885MAOB 274/4885 |
| US-20100230634-A1 | METHOD FOR PRODUCING BIPHENYL DERIVATIVE | CYP2E1, DDT, B2M | TAAR1 4209/4885AOC3 1215/4885MAOB 1596/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TAAR1 1170/4885AOC3 826/4885MAOB 518/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | TAAR1 2082/4885AOC3 149/4885MAOB 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.